Post by nita on Jan 6, 2021 8:44:46 GMT
The global hereditary angioedema treatment market to gain from increasing incidences of genetic mutation. Recently Fortune Business Insights, published a report titled, “Hereditary Angioedema Treatment Market Size, Share and Global Trend by Drug Class (C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors), Application (Prophylaxis, Treatment), Route of Administration (IV, Subcutaneous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) and Geography Forecast till 2025.” As per the report, the global hereditary angioedema treatment market was worth US$ 1883.1 Mn in 2017. The global market is anticipated to expand at a CAGR of 16.8% and reach US$ 6533.3 Mn by the end of 2025. The report classifies the global hereditary angioedema treatment market in various segments and offer a comprehensive overview.
For more information in the analysis of this report, visit: www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164
some of the key players in the global Hereditary Angioedema Treatment Market:
BIOCRYST PHARMACEUTICALS INC.
Ionis Pharmaceuticals Inc.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals Inc.
Adverum
According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute the expansion of the hereditary angioedema treatment market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, increasing number of product innovations in the region backed by high presence of hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the hereditary angioedema treatment market.
C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period
In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.
Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.
Shire, CSL Behring, and Pharming Group NV to Lead the Global Market
The global hereditary angioedema treatment market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.
For more information in the analysis of this report, visit: www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164
some of the key players in the global Hereditary Angioedema Treatment Market:
BIOCRYST PHARMACEUTICALS INC.
Ionis Pharmaceuticals Inc.
Attune Pharmaceuticals
Arrowhead Pharmaceuticals Inc.
Adverum
According to the report, the hereditary angioedema treatment market in North America was valued at US$ 1752.2 Mn in 2017. The growth witnessed is attributable to high prevalence of hereditary angioedema in the region. North America may remain dominant in the global market through the forecast period (2018-2025) also. Presence of an established healthcare system and increasing healthcare expenditure are a few factors anticipated to contribute the expansion of the hereditary angioedema treatment market in North America. The report also predicts the market in Asia Pacific to witness impressive growth. Increasing medical tourism in nations such as China and India will create lucrative growth opportunities for the market in the region. Besides this, increasing number of product innovations in the region backed by high presence of hereditary angioedema drugs manufacturers will give tailwinds to growth witnessed by the hereditary angioedema treatment market.
C-1 Esterase Inhibitor Segment to Dominate Global Market During Forecast Period
In terms of drug class, the C-1 esterase inhibitor is the most popular drug and dominated the global hereditary angioedema treatment market in 2017. The segment accounted for 61.3% of the global market in 2017. The trend is unlikely to change during the forecast period 2018-2025 owing to the drug’s reliability among patients and practitioners.
Increasing awareness about the disorder and rising prevalence of the hereditary angioedema are some factors expected to drive the global hereditary angioedema treatment market during the forecast period. Additionally, technological developments in the hereditary angioedema treatment devices and equipment is expected to boost the global market.
Shire, CSL Behring, and Pharming Group NV to Lead the Global Market
The global hereditary angioedema treatment market is witnessing entry of new players in the market. However, at present Pharming Group NV, Shire, and CSL Behring are together leading the global market owing to the organization’s strong distribution network. Some of the other companies operating in the global hereditary angioedema treatment market are BIOCRYST PHARMACEUTICALS INC., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals Inc., and Adverum.